Abstract: Prolonging the circulation of an imaging agent is vital for making it suitable for blood pool (vascular) imaging. Medical applications of vascular imaging include cardiovascular disease, abnormal capillary permeability, and tumor neovascularity. As low molecular weight computerized tomography (CT) enhancement agents are characterized by inconveniently fast clearance, macromolecular compounds (both natural and synthetic) have gained a wide recongnition for possessing better characteristics for performing blood imaging tasks. Herein, the syntheses and characterization of a new water-soluble triiodo amino acid, 3-[(N,N-dimethylaminoacetyl)amino]-a-ethyl-2,4,6-triiodobenzenepropanoic acid (DMAA-IPA) and its Starburst PAMAM generation 4.0 dendrimer conjugate, G-4-(DMAA-IPA) 37 are described. The applicability of G-4-(DMAA-IPA) 37 as a potential macromolecular angiographic CT contrast agent is discussed. The linear relationship between organically bound iodine concentration and CT Hounsfield units has been established thus allowing for quantification uses of CT imaging as well.
INTRODUCTION
Medical imaging has made enormous advances since its origins with the discovery of X-rays by Roentgen in 1895. Today, computerized tomography (CT) is a widely available imaging method with high spatial resolution. CT imaging requires the presence of an element of an atomic weight and radiographic density higher than those of biological tissue such as, for example, iodine. The concentration of iodine necessary for an adequate CT contrast agent is rather high, greater than 1 mg/mL, which requires the injection of 30-50 g of iodine, or 70-120 g of contrast agent. Therefore, the first X-ray CT contrast agent, sodium iodide, turned out to be rather toxic. Subsequently, iodine had to be covalently bound to an organic molecule, and the most suitable carrier for organic iodine was the benzene ring. All presently available CT imaging agents are non-specific compounds, mostly iodinated ionic or non-ionic small molecules, like N- (2,3-dihydroxypropyl Fig. 1 ). They are not restrained within the vascular system, distribute quickly in the extracellular space, [1] [2] [3] [4] and also clear rapidly from the human body. As a result, current angiographic imaging (high contrast in the cardio-vascular system) is only possible on a time scale limited to minutes or even seconds, a rather inconvenient circumstance from both a clinical and patient's points of view. Therefore, the objective of extensive research efforts, pursued by several researchers, has been the development of macromolecular CT contrast agents to provide both in higher and in longer-lived cascular concentrations has been pursued by several researchers. There are quite a few reports of macromolecular, water-soluble iodinated CT contrast agents in the literature, most of which are based on linear synthetic polymers, functionalized starches, or serum albumin. [5] [6] [7] [8] [9] In addition to cardiovascular imaging, another possible area of application for macromolecular CT contrast agents is non-invasive monitoring of delivery of therapeutic agents into the brain by convection-enhanced delivery (CED). 10 The structures and sizes of all carriers mentioned above are presently optimized, but to date, none of these agents have reached a status of routine clinical application. 11 Among the currently commercially available synthetic macromolecules are Starburst PAMAM dendrimers, spherical nanoparticles composed of an ethylenediamine initiator core, repeating polyamidoamino units and primary amino groups on the surface. These agents can be produced in successive "generations", each with a specified and defined size, molecular weight, and number of terminal amino groups. [12] [13] [14] [15] [16] Because of their well-defined characteristics and lack of immunoge-nicity, PAMAMs are finding utility in a variety of applications, many of which are biological in nature. Dendrimers are currently under investigation as potential polymeric carriers of contrast agents for magnetic resonance imaging (MRI) [17] [18] [19] [20] and as free radical life supporters for electron paramagnetic resonance (EPR) imaging. 21 Herein, we report the synthesis and characterization of a new iodine-labeled dendrimer, G-4-(DMAA-IPA) 37 (Fig. 2) , based on Generation 4.0 (G-4) Starburst PAMAM dendrimer.
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EXPERIMENTAL
Materials
Iodopanoic acid (3-amino-a-ethyl-2,4,6-triiodobenezenepropanoic acid, 1) was purchased from TCI America (Portland, Oregon). Generation 4.0 Starburst PAMAM dendrimer, anhydrous dimethylformamide (DMF), dimethylamine hydrochloride, triethylamine, N-hydroxysuccinimide and 1,3-dicyclohexylcarbodiimide (DCC) were purchased from Sigma-Aldrich (Milwaukee, Wisconsin). 3-[(Chloroacetyl)amino]-a-ethyl-2,4,6-triiodobenezenepropanoic acid (2) was prepared as described elsewhere. 22 Proton and 13 C-NMR spectra were recorded on a Varian Gemini 300 instrument (Palo Alto, California). Chemical shifts were expressed as ppm as referenced to tetramethylsilane (TMS). FAB mass spectra were obtained on an ABB Inc. Extrel 400 instrument (Pittsburgh, Pennsylvania). Elemental analyses were performed by Galbraith Laboratories, Inc. (Knoxville, Tennessee). Chromatographic separations were performed on silica gel columns by flash (Silica Gel 60, 0.035-0.070 mm; Fluka).
3-[(N,N-Dimethylaminoacetyl)amino]-a-ethyl-2,4,6-triiodobenezenepropanoic acid (DMAA-IPA, 3).
To a solution of 3-[(chloroacetyl)amino]-a-ethyl-2,4,6-triiodobenezenepropanoic acid 2 (26.0 g, 40.2 mmol) in DMF (500 cm 3 ) and methanol (500 cm 3 ) were added dimethylamine hydrochloride (40 g, 490 mmol) and triethylamine (100 cm 3 ) and the reaction mixture was heated at 70°C for 18 h. The product was isolated with a Waters Delta Prep 3000 Preparative Chromatography System equipped with a Waters Delta Pak C18 100A 30 mm´30 cm column (Milford, Massachusetts) using a water/acetonitrile gradient where both mobile phases contained 0.1 % TFA. The fractions containing DMAA-IPA were combined, concentrated, and the residue lyophilized to yield 3 as its trifluoroacetate salt. Yield: 15 (4) . To a solution of 3 (10.0 g, 13 mmol) in DMF (100 cm 3 ) were added N-hydroxysuccinimide (3.2 g, 27 mmol) and DCC (5.8 g, 28.1 mmol). The reaction mixture was stirred for 18 h at ambient temperature. The solvent was evaporated almost to dryness and the residue subjected to gradient elution flash chromatography (ethyl acetate/methanol/triethylamine). Yield: 8.0 g (82 %). FAB MS: 754 (M+H) + . The hygroscopic N-hydroxysuccinimidyl active ester was unstable and was immediately used in the next step without further purification.
G-4-(DMAA-IPA) 37 (5) . The parent G-4 dendrimer (1.4 g) was reacted with a 100 % excess of 4 for 48 h at 80°C in 300 cm 3 DMSO in the presence of 50 cm 3 triethylamine (TEA). The latter was removed by evaporation, and the solution was diluted with 10 % aqueous acetic acid and methanol. The excess active ester and N-hydroxysuccinimide were removed by ultrafiltration with de-ionized water using an Amicon stirred cell (Millipore, Bedford, Massachusetts) fitted with a 10 kD membrane. Occasional precipitation of a solid material in the cell occurred. In such cases, the precipitate was brought back into solution by the addition of sufficient portions of methanol, after which the fil-tration was continued until no more precipitation occurred upon addition of water. Thereafter, 1 % aqueous NaCl (40 cm 3 ) was added and the filtration was continued until the inside solution tested negative for Cl -ion (0.1 M AgNO 3 ). The resulting solute was lyophilized to obtain the desired iodinated dendrimer G-4-(DMAA-IPA) 37 CT Hounsfield units measurements. The aqueous samples containing different concentrations of G-4-(DMAA-IPA) 37 (5) (0.400 cm 3 in 0.15 M acetic acid) were imaged using a helical GE model QXI unit (General Electric Medical Systems, Milwaukee, Wisconsin) and the following parameters: a displayed field of view (DFOV) 50 cm, 120 kV, 250 mA, slice thickness 5 mm, and a 512 matrix. The CT images were analyzed using an appropriate software package (MEDx Sensor Systems, Inc., Sterling, Virginia) running on a Sun workstation (Sun Microsystems, Palo Alto, California).
RESULTS AND DISCUSSION
Among the numerous triiodinated aromatic compounds described in the literature, we chose iodopanoic acid (IPA, iopanoic acid, 3-amino-a-ethyl-2,4,6-triiodobenezenepropanoic acid, 1, Fig. 2 ) due to this particular compound having both aniline and carboxylic acid groups that might be suitable sites for further modification as well as for conjugation to macromolecules. IPA has been used to image the gallbladder, 23 and more recently, 1,3,5-trialkyl-2,4,6-triiodobenzenes were considered as alternatives of barium sulfate for examinations of the gastrointestinal (GI) tract. 24 Recently, we reported the preparation of an iodopanoic acid-bovine serum albumine (IPA-BSA) conjugate and its application in CT imaging of the convective distribution of macromolecules in the primate brain. 10 However, our attempts to saturate the G-4 dendrimer surface with 1 yielded only intractable solids. This was most likely due to the rather lipophilic nature of IPA now effectively coating the exterior of the macromolecule and eliminating adequate hydrophilic interactions for good physiological aqueous solubility characteristics. This was somewhat surprising in light of the aniline group still being available, yet we also have noted low accessibility and reactivity of this aniline. In response to this result, we synthesized the more hydrophilic 3-[(N,N-dimethylaminoacetyl)ami- no]-a-ethyl-2,4,6-triiodobenzenepropanoic acid (DMAA-IPA, 3). It was specifically designed so that the total positive charge and the solubility of the dendrimer are not significantly affected after the modification of its surface by providing an accessible tertiary amino group to the triiodo moiety. The synthetic route to DMAA-IPA and G-4-(DMAA-IPA) 37 is presented in Fig. 3 . Iodopanoic acid 1 was first converted to 3-[(chloroacetyl)amino]-a-ethyl-2,4,6-triiodobenzenepropanoic acid 2 using a previously reported acylation procedure. 22 This compound was then treated with an excess of dimethylamine. The trifluoroacetate of DMAA-IPA (3) was isolated from the reaction mixture by preparative reverse phase chromatography. Amino acid 3 was then subsequently converted into its active ester 4 by treatment with N-hydroxysuccinimide in the presence of 1,3-dicyclohexylcarbodiimide (DCC). In the final step, the parent G-4 dendrimer (1.4 g) was reacted with a 100 % excess of 4 for 48 h at 80°C in 300 mL DMSO and in the presence of 50 mL triethylamine (TEA). The product, G-4-(DMAA-IPA) 37 , was isolated by ultrafiltration.
A pivotal characteristic of any potential CT contrast agent is its heavy element content, the latter being accountable for the clinically relevant X-ray absorbing properties of the material. content confirmed the suitability of this agent for CT imaging purposes. The full characterization of G-4-(DMAA-IPA) 37 using a variety of methods has been published elsewhere. 25 In brief, the average number of DMAA-IPA units on the G-4 dendrimer surface was found to be 37 and its average molecular weight -37,000 g/mol (as determined by MALDI-TOF) or 42,000 g/mol (as determined by MALS).
The hydrodynamic radius (R h ) of G-4-(DMAA-IPA) 37 was determined to be 2.4 nm, much smaller than that of BSA, a globular protein with a molar mass of 66,431 g/mol and R h of 3.4 nm. This is in agreement with the very dense structure of G-4-(DMAA-IPA) 37 concurring with its high iodine content.
One possible advantage of CT over MRI is the linear relationship that exists between concentration and signal. Herein we demonstrate that such a linear relationship between dendrimer-bound iodine concentration and the opaqueness of the solution, as expressed in CT Hounsfield units, indeed exists (Fig. 4) . Thus, it should be rather straightforward to use CT scanning to measure the concentration of iodine-labeled dendrimers [such as G-4-(DMAA-IPA) 37 ] in each voxel of tissue or blood for quantitative applications as well. Currently, murine model studies are under way for further biological evaluation of G-4-(DMAA-IPA) 37 as a potential angiographic CT contrast agent. 
